Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Abbott outbids Biogen for Facet's multiple sclerosis antibody.

× No keyword cloud information.

3 in total

1. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.

Authors: Bibiana Bielekova; Marta Catalfamo; Susan Reichert-Scrivner; Amy Packer; Magdalena Cerna; Thomas A Waldmann; Henry McFarland; Pierre A Henkart; Roland Martin
Journal: Proc Natl Acad Sci U S A Date: 2006-04-03 Impact factor: 11.205

Review 2. Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey.

Authors: Thomas A Waldmann
Journal: J Clin Immunol Date: 2007-01-11 Impact factor: 8.317

3. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.

Authors: Daniel Wynn; Michael Kaufman; Xavier Montalban; Timothy Vollmer; Jack Simon; Jacob Elkins; Gilmore O'Neill; Lauri Neyer; James Sheridan; Chungchi Wang; Alice Fong; John W Rose
Journal: Lancet Neurol Date: 2010-02-15 Impact factor: 44.182

3 in total

2 in total

1. Biogen's once-monthly MS injection gets FDA nod.

Authors:
Journal: Nat Biotechnol Date: 2016-07-12 Impact factor: 54.908

Review 2. Disease-modifying therapy of pediatric multiple sclerosis.

Authors: Tanuja Chitnis
Journal: Neurotherapeutics Date: 2013-01 Impact factor: 7.620

2 in total